Akers Biosciences Stock Price, News & Analysis (LON:AKR)

GBX 31 +1.00 (+3.33 %)
(As of 02/22/2018 03:07 AM ET)
Previous CloseGBX 30
Today's RangeN/A
52-Week RangeGBX 10.50 - GBX 189.98
VolumeN/A
Average Volume11,162 shs
Market Capitalization£12.02 million
P/E Ratio-54.39
Dividend YieldN/A
BetaN/A

About Akers Biosciences (LON:AKR)

Akers Biosciences logoAkers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company's primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

Receive AKR News and Ratings via Email

Sign-up to receive the latest news and ratings for AKR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolLON:AKR
CUSIPN/A
Phone+1-856-8488698

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-54.3859649122807
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.57)
Net IncomeN/A
Net Margins-174.25%
Return on Equity-104.25%
Return on Assets-78.13%

Miscellaneous

EmployeesN/A
Outstanding Shares9,580,000

Akers Biosciences (LON:AKR) Frequently Asked Questions

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the London Stock Exchange (LON) under the ticker symbol "AKR."

Who are some of Akers Biosciences' key competitors?

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the folowing people:

  • Raymond Francis Akers Jr., Ph.D., Executive Chairman of the Board, Co-Founder, Secretary, Chief Scientific Director (Age 58)
  • John J. Gormally, Chief Executive Officer, Director (Age 61)
  • John C. Cheneval, Executive Vice President, Sales and Marketing
  • Gary M. Rauch, Senior Vice President - Finance, Treasurer (Age 59)
  • Christopher Ellis, Vice President - Global Marketing
  • Christopher C. Schreiber, Director (Age 52)
  • Richard C. Tarbox III, Director (Age 65)
  • Bill Joe White, Director (Age 56)
  • Robert E. Andrews, Non-Executive Director (Age 53)
  • Raza Bokhari, Non-Executive Director (Age 48)

How do I buy Akers Biosciences stock?

Shares of Akers Biosciences and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Akers Biosciences' stock price today?

One share of Akers Biosciences stock can currently be purchased for approximately GBX 31.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of £12.02 million.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 Grove Rd, WEST DEPTFORD, NJ 08086-2231, United States. The company can be reached via phone at +1-856-8488698.


MarketBeat Community Rating for Akers Biosciences (AKR)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akers Biosciences (LON:AKR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AGBX 150

Akers Biosciences (LON:AKR) Consensus Price Target History

Price Target History for Akers Biosciences (LON:AKR)

Akers Biosciences (LON:AKR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/21/2017FinnCapReiterated RatingCorporateView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Earnings History for Akers Biosciences (LON:AKR)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Akers Biosciences (LON:AKR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Akers Biosciences (LON:AKR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akers Biosciences (LON AKR)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Akers Biosciences (LON AKR) News Headlines

Source:
DateHeadline
Update RE Admission of Shares - London South East (blog)Update RE Admission of Shares - London South East (blog)
www.lse.co.uk - January 17 at 4:05 PM
Closing of Public Offering - London South East (blog)Closing of Public Offering - London South East (blog)
www.lse.co.uk - December 22 at 5:43 PM
Akers Biosciences Announces Closing of $6900000 Public Offering - GlobeNewswire (press release)Akers Biosciences Announces Closing of $6900000 Public Offering - GlobeNewswire (press release)
globenewswire.com - December 22 at 5:43 PM
Akers Biosciences Announces Closing of $6,900,000 Public OfferingAkers Biosciences Announces Closing of $6,900,000 Public Offering
finance.yahoo.com - December 22 at 11:08 AM
Akers Biosciences Secures Further Intellectual Property Protection for Akers Wellness Line - GlobeNewswire (press release)Akers Biosciences Secures Further Intellectual Property Protection for Akers Wellness Line - GlobeNewswire (press release)
globenewswire.com - December 8 at 11:08 AM
Akers Biosciences Secures Further Intellectual Property Protection for Akers Wellness LineAkers Biosciences Secures Further Intellectual Property Protection for Akers Wellness Line
finance.yahoo.com - December 8 at 11:08 AM
Akers Biosciences Inc (AKR) Rating Reiterated by FinnCapAkers Biosciences Inc (AKR) Rating Reiterated by FinnCap
www.americanbankingnews.com - November 23 at 10:40 PM
Is Akers Biosciences Inc (AKER) Thriving Or Barely Surviving In The Healthcare Sector?Is Akers Biosciences Inc (AKER) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - November 16 at 10:57 AM
Akers Biosciences, Inc. to Host Earnings CallAkers Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - November 16 at 10:57 AM
Akers Biosciences Announces Q3 2017 EarningsAkers Biosciences Announces Q3 2017 Earnings
finance.yahoo.com - November 16 at 10:57 AM
Akers Biosciences Announces Conference Call to Discuss Q3 2017 Earnings - GlobeNewswire (press release)Akers Biosciences Announces Conference Call to Discuss Q3 2017 Earnings - GlobeNewswire (press release)
globenewswire.com - November 15 at 2:18 AM
Akers Biosciences UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer - GlobeNewswire (press release)Akers Biosciences' UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer - GlobeNewswire (press release)
globenewswire.com - November 15 at 2:18 AM
PDMR Shareholding and Issue of Equity - London South East (blog)PDMR Shareholding and Issue of Equity - London South East (blog)
www.lse.co.uk - October 20 at 10:39 PM
Warrant Amendment and Exercise - London South East (blog)Warrant Amendment and Exercise - London South East (blog)
www.lse.co.uk - October 14 at 1:42 AM
Can Akers Biosciences Inc (AIM:AKR) Improve Your Portfolio Returns?Can Akers Biosciences Inc (AIM:AKR) Improve Your Portfolio Returns?
finance.yahoo.com - September 15 at 4:01 PM
Appointment of US VP of Sales & Distribution - London South East (registration) (blog)Appointment of US VP of Sales & Distribution - London South East (registration) (blog)
www.lse.co.uk - September 8 at 1:44 AM
Akers Biosciences Hires Medical Device Specialist to Lead US Sales and DistributionAkers Biosciences Hires Medical Device Specialist to Lead US Sales and Distribution
finance.yahoo.com - September 7 at 3:39 PM
Akers Biosciences, Inc. :AKR-GB: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017Akers Biosciences, Inc. :AKR-GB: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 4 at 9:17 PM
Akers Biosciences Inc (AKR) Earns "Corporate" Rating from FinnCapAkers Biosciences Inc (AKR) Earns "Corporate" Rating from FinnCap
www.americanbankingnews.com - August 27 at 3:44 PM
See what the IHS Markit Score report has to say about Akers Biosciences Inc.See what the IHS Markit Score report has to say about Akers Biosciences Inc.
finance.yahoo.com - August 10 at 5:09 PM
Akers Biosciences Announces Board ChangesAkers Biosciences Announces Board Changes
finance.yahoo.com - August 8 at 3:39 PM
Akers Biosciences Announces Second Quarter Trading Update - BenzingaAkers Biosciences Announces Second Quarter Trading Update - Benzinga
www.benzinga.com - August 5 at 3:30 PM
Form S-3 Registration Statement - London South East (registration) (blog)Form S-3 Registration Statement - London South East (registration) (blog)
www.lse.co.uk - July 5 at 7:16 AM
Akers Biosciences Announces Q1 2017 Earnings / Significant Cost Reductions and Progress Towards BreakevenAkers Biosciences Announces Q1 2017 Earnings / Significant Cost Reductions and Progress Towards Breakeven
www.finanznachrichten.de - May 16 at 3:28 PM
Akers Biosciences narrows loss, but revenue falls - MarketWatchAkers Biosciences narrows loss, but revenue falls - MarketWatch
www.marketwatch.com - May 16 at 7:08 AM
Akers Biosciences to Commercialize Heparin PF4 Rapid Test in Puerto Rico - MarketWatchAkers Biosciences to Commercialize Heparin PF4 Rapid Test in Puerto Rico - MarketWatch
www.marketwatch.com - April 11 at 8:18 AM
Akers Biosciences Announces Closing of Public Offering - MarketWatchAkers Biosciences Announces Closing of Public Offering - MarketWatch
www.marketwatch.com - January 14 at 3:25 PM
Form 8-K Akers Biosciences Inc For: Jan 13 - StreetInsider.comForm 8-K Akers Biosciences Inc For: Jan 13 - StreetInsider.com
www.streetinsider.com - January 13 at 3:49 PM
South Jersey maker of rapid screening tests plans $2M stock saleSouth Jersey maker of rapid screening tests plans $2M stock sale
www.bizjournals.com - January 11 at 3:43 PM
Akers Biosciences halves loss; revenue up 262%Akers Biosciences halves loss; revenue up 262%
www.marketwatch.com - November 14 at 12:09 PM
Akers Bio Share ChatAkers Bio Share Chat
www.lse.co.uk - June 27 at 8:09 AM

SEC Filings

Akers Biosciences (LON:AKR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Akers Biosciences (LON AKR) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.